Kiniksa Pharmaceuticals International, plc (KNSA) Business Profile

What it does

Kiniksa Pharmaceuticals International is a biopharmaceutical company focused on cardiovascular diseases. It sells ARCALYST in the United States, primarily for recurrent pericarditis, an inflammatory disease in which the sac surrounding the heart becomes inflamed again after an earlier episode. The company’s chief executive officer is Sanj K. Patel.

ARCALYST blocks two inflammatory signaling proteins, IL-1α and IL-1β. Patients receive it as a weekly injection under the skin. It is approved in the United States for recurrent pericarditis in adults and children 12 years and older. It is also approved for certain rare inflammatory conditions known as CAPS and for maintenance of remission in DIRA, subject to age or weight requirements.

Kiniksa licensed ARCALYST from Regeneron and sells it through specialty pharmacies that deliver the medicine to patients. The companies share profits from sales and proceeds from third-party licensing.

Kiniksa is developing KPL-387, an investigational antibody for recurrent pericarditis. The company says it could be administered by patients once a month under the skin. Its pivotal Phase III study is enrolling and dosing patients. Kiniksa is also developing KPL-1161, a related investigational antibody designed for a longer duration of action, and exploring strategic alternatives for abiprubart, an autoimmune disease candidate.

How it makes money

Kiniksa earns product revenue by selling ARCALYST. It recognizes net revenue when the customer obtains control of the product, typically when the logistics provider ships it. Sales continue as patients receive treatment, but the company’s revenue depends on prescriptions, treatment duration and patient access rather than a subscription contract.

Net product revenue was $677.6 million in FY2025; ARCALYST revenue was $286 million in the third quarter of 2026.

The reported product revenue figure is net of estimated discounts and allowances, including rebates, returns, copay assistance and fees paid to specialty pharmacies and distributors. Kiniksa aims to secure patient access at a price reflecting ARCALYST’s value and offers affordability programs for eligible patients. The supplied disclosures do not give a per-patient price.

ARCALYST is Kiniksa’s only commercial product. Revenue from its pharmaceutical segment was $677.6 million in FY2025. Although Kiniksa records product sales, it does not retain all the resulting profit: Regeneron receives an equal share of ARCALYST profits after certain manufacturing and commercialization costs are deducted.

The company can also earn payments through licensing arrangements. Huadong has rights to develop and commercialize ARCALYST in its territory, and Kiniksa is eligible for contingent sales milestones and royalties. Kiniksa also has a license agreement with Genentech that provides for possible milestone payments and royalties. Payments tied to those agreements depend on specified events or sales, rather than being assured recurring revenue. ARCALYST licensing proceeds are also shared evenly with Regeneron.

Customers and how it sells

Kiniksa’s direct ARCALYST customers are principally specialty pharmacies supplied through a third-party logistics provider. The pharmacies deliver the medicine to patients by mail. Prescribers, patients and payers also influence access and demand: Kiniksa uses a specialty salesforce, medical affairs staff, payer teams and patient services to reach them.

The company estimates that approximately 40,000 patients in the United States seek and receive treatment for recurrent pericarditis each year. Its initial commercial focus has been patients with persistent disease, multiple recurrences and inadequate responses to conventional therapy. Kiniksa also seeks to reach patients earlier, including those experiencing a first recurrence.

At the end of the third quarter of 2026, Kiniksa reported around 5,450 cumulative ARCALYST prescribers for recurrent pericarditis. It said around 30% of that group were repeat prescribers.

ARCALYST is approved for sale in the United States, and Kiniksa expects to derive substantially all product revenue there for the foreseeable future. Its license from Regeneron covers worldwide rights outside the Middle East and North Africa, with exclusions for oncology and local administration to the eye or ear. Kiniksa granted Huadong exclusive development and commercialization rights in the Asia Pacific region, excluding Japan.

Suppliers and costs

Regeneron manufactures and supplies all of Kiniksa’s ARCALYST requirements for development and commercial activities under a supply agreement. Kiniksa is transferring the drug-substance manufacturing process to Samsung and analytical testing methods to new contract laboratories. Other contractors handle filling, labeling, packaging and shipping.

Kiniksa does not own or operate late-stage manufacturing facilities. It has a development and manufacturing facility for certain research, preclinical and other clinical work, but relies on contract manufacturers for late-stage candidates and commercial production. It also uses contract manufacturers for clinical product candidates.

Cost of goods sold includes ARCALYST production and distribution, supply-chain and quality expenses, and costs associated with the manufacturing technology transfer. Collaboration expenses include Regeneron’s share of ARCALYST profits. Kiniksa also spends on research and development, sales, marketing and patient access.

The company said higher ARCALYST revenue in the third quarter of 2026 increased cost of goods sold and collaboration expenses. Development of KPL-387 increased research and development spending, while efforts to reach more ARCALYST patients increased selling, general and administrative spending.

Competitive position

At year-end 2025, Kiniksa was not aware of another FDA-approved therapy for recurrent pericarditis, although it identified several companies developing treatments. Cardiol Therapeutics is studying its oral drug CardiolRx in a Phase 3 trial for patients discontinuing an IL-1 blocker. Ventyx Biosciences is studying VTX2735 in recurrent pericarditis. R-Pharm International’s goflikicept is marketed in Russia, but had no active United States trial when described by Kiniksa.

Other therapies can inhibit the same inflammatory signals without being approved for recurrent pericarditis. These include anakinra, marketed as KINERET by Swedish Orphan Biovitrum, and lutikizumab, which AbbVie is developing for other diseases. Conventional treatments for pericarditis include NSAIDs, colchicine and corticosteroids.

ARCALYST has FDA approval for recurrent pericarditis, and the FDA granted it orphan drug exclusivity for pericarditis in March 2021. Kiniksa has a specialty salesforce and patient-support services intended to help patients access and use the medicine.

Our reading: ARCALYST’s approved position and orphan exclusivity provide a regulatory advantage, but competing drugs in development could limit its durability. Our reading: The salesforce and support network help Kiniksa reach prescribers and patients, although the evidence does not establish that those services cannot be replicated.

Growth opportunities

Kiniksa plans to grow ARCALYST use among patients with multiple recurrences and patients earlier in their disease. The company estimates an annual United States population of 14,000 patients with multiple recurrences and an additional 26,000 experiencing a first recurrence. It reported that penetration of the multiple-recurrence population reached 23% at the end of the third quarter of 2026.

The company is investing in prescriber education, patient identification and a targeted consumer campaign. It also seeks to establish ARCALYST as a treatment used as soon as appropriate after diagnosis and for the duration of the disease. Kiniksa expects 2026 ARCALYST sales of $1.045 billion-$1.050 billion.

KPL-387 is another development path. Kiniksa believes its potential once-monthly injection could provide another treatment option and expand the recurrent pericarditis market. The company expects data from its pivotal Phase III trial in the second half of 2027. A separate study is evaluating transitions from standard therapies to KPL-387 alone.

KPL-1161 is designed for a longer drug half-life, which Kiniksa believes could support quarterly dosing. The company expects to begin a Phase I program by the end of 2026, but has not disclosed its planned development indications. It is also investigating ARCALYST in cardiac sarcoidosis through a collaborative study and can pursue licensing or other partnerships for its programs.

Structural risks

• Commercialization and access: Kiniksa may be unable to sustain ARCALYST commercialization or obtain and maintain reimbursement and broad patient access. Its sales personnel may also have difficulty reaching prescribers, and demand for approved products may fall.

• Manufacturing: Kiniksa depends on third-party manufacturers. Delays in producing sufficient quantities at acceptable cost or quality, including delays in transferring ARCALYST manufacturing, could disrupt commercialization.

• Competition: Current or future alternative therapies and biosimilars could compete with ARCALYST or future products. Convenience and ease of administration relative to alternatives can affect their use.

• Clinical development and approval: Kiniksa may be unable to demonstrate acceptable safety and efficacy, enroll trial participants or commercialize candidates even if they are approved. KPL-387’s efficacy remains to be demonstrated in its ongoing pivotal Phase III trial.

• Protection and regulation: Kiniksa may be unable to establish, maintain or defend patent, trade-secret or regulatory exclusivity protection. Regulatory investigations can require costly recalls, product modifications or withdrawal from the market.

Bottom line

Our reading

Kiniksa is a commercial drug company whose product sales depend on ARCALYST and whose profit from that medicine is shared with Regeneron. Its opportunity rests on reaching more recurrent pericarditis patients and developing additional therapies, while its exposure includes manufacturing dependence, access and competition. The pipeline could broaden the business, but its candidates still require clinical development and approval.